ScripJiangsu Hengrui Pharmaceuticals, China’s top drug developer by size of pipeline, is set to stage the world’s biggest new share sale by a pharmaceutical company so far in 2025 by raising up to HKD9.89b
In VivoChinese companies are conducting multiple clinical trials for obesity medicines, especially domestically, and ramping up the production of semaglutide generics, meaning there’s no lack of drug options
ScripChinese companies are conducting multiple clinical trials for obesity medicines, especially domestically, and ramping up the production of semaglutide generics, meaning there’s no lack of drug options
ScripInvestors are acutely focused on the loss of exclusivity (LOE) of Merck & Co.’s mega-blockbuster Keytruda (pembrolizumab) in 2028, but head of global clinical development and chief medical officer